ArticleAsian Pacific journal of cancer prevention : APJCP2026
Differential Clinical Outcomes of Palliative Radiotherapy among Different Molecular Subtypes of Metastatic Breast Cancer: A Prospective Study.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMolecular classification is used to tailor systemic therapy in breast cancer (BC). However, there is a paucity of literature correlating the response to radiotherapy with molecular subtypes of metastatic breast cancer (MBC) This prospective study intends to evaluate the differences in clinical outcomes in the different molecular subtypes of MBC to hypofractionated palliative radiotherapy (HPRT).
methodsMBC patients between December 2021 to September 2022, with Karnofsky Performance status > 70, were enrolled and treated with HPRT. All patients received systemic therapy. All patients were evaluated until 12 months post-radiotherapy. The molecular subtype of BC, local control (LC), and progression-free survival (PFS) were documented.
resultEighty patients were recruited, with a mean age of 51 ± 10.48 years. Twelve of 80 patients expired, and 16 of 80 patients were lost to follow-up. The molecular subtypes were: Luminal B (37.5%), Luminal A (30%), TNBC (20%) and HER2+ (12.5%). At 6 months post-RT, 61.5% patients had local control (LC) at their metastatic site, whereas 38.5% had Progressive disease (PD). At 12 months, 71.1% had LC at the metastatic site, and 28.9% had progression. Local control at 6 months by subtype: Luminal A - 83%, Luminal B - 60%, HER2+ - 50% and TNBC - 31.2% (p = 0.01). The median progression-free survival (PFS) of the study group was 6 months (95% CI: 4.78-7.22), with TNBC patients performing the poorest.
conclusionLuminal subtypes have better local control and progression-free survival post-HPRT compared to TNBC and HER2+ subtypes, which can further be used to stratify radiotherapy fractionation schedules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.